Earnings summaries and quarterly performance for NextCure.
Executive leadership at NextCure.
MR
Michael Richman
Detailed
President and Chief Executive Officer
CEO
KS
Kevin Shaw
Detailed
Senior Vice President, General Counsel
SK
Sourav Kundu
Detailed
Senior Vice President, Development & Manufacturing
SC
Steven Cobourn
Detailed
Chief Financial Officer
TM
Timothy Mayer
Detailed
Chief Operating Officer
UG
Udayan Guha
Detailed
Chief Medical Officer
Board of directors at NextCure.
Research analysts covering NextCure.
Recent press releases and 8-K filings for NXTC.
NextCure Provides Business Update and Preliminary Year-End 2025 Financials
NXTC
Guidance Update
New Projects/Investments
- NextCure reported preliminary cash, cash equivalents, and marketable securities of approximately $41.8 million as of December 31, 2025, with financial resources expected to fund operations into the first half of 2027.
- Data from the SIM0505 (CDH6 ADC) Phase 1 dose escalation study are anticipated in Q2 2026.
- A trial progress update for the LNCB74 (B7-H4 ADC) Phase 1 dose escalation study is now expected in the second half of 2026, delayed from the previously anticipated first half of 2026 to accommodate enrollment.
Jan 23, 2026, 12:20 PM
NextCure Updates on Clinical Programs and Financial Position
NXTC
Guidance Update
New Projects/Investments
- NextCure anticipates presenting SIM0505 (CDH6 ADC) Phase 1 dose escalation data in Q2 2026.
- Proof-of-concept data for LNCB74 (B7-H4 ADC) Phase 1 is now anticipated in the second half of 2026, a delay from the previously expected first half of 2026.
- As of December 31, 2025, NextCure reported preliminary cash, cash equivalents, and marketable securities of approximately $41.8 million.
- The company expects its current financial resources to fund planned operating expenses and capital expenditures into the first half of 2027.
Jan 23, 2026, 12:00 PM
NextCure enters into $14.5 million At The Market Offering Agreement
NXTC
- NextCure, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC on December 19, 2025.
- Under this agreement, NextCure, Inc. may sell up to an aggregate sales price of $14,500,000 of its common stock through H.C. Wainwright & Co., LLC acting as the agent.
- H.C. Wainwright & Co., LLC will receive 3.0% of the gross proceeds from the sale of shares as compensation.
- The net proceeds from the offering are intended for general corporate purposes and working capital, including funding preclinical studies, clinical trials, and advancing product candidates.
Dec 19, 2025, 10:31 PM
NextCure Provides Updates on ADC Programs and Financial Outlook
NXTC
New Projects/Investments
Guidance Update
- NextCure is developing two antibody-drug conjugates (ADCs): SIM0505 (targeting CDH6) with partner Simcere Zaiming and LNCB74 (targeting B7-H4) with LigaChem.
- Both SIM0505 and LNCB74 are anticipated to report Phase 1 dose escalation data in the first half of 2026. SIM0505 has demonstrated strong safety and clinical responses, while LNCB74 has proven extremely safe, allowing for higher doses.
- The company's cash balance of less than $50 million, including a recent $21.5 million PIPE, is projected to fund operations into the first half of 2027.
- NextCure plans to conduct another financing at the beginning of 2026 to support the advancement of its programs into Phase 2.
- NextCure is seeking to spin out or partner its non-oncology assets, which include programs for osteogenesis imperfecta and Alzheimer's disease.
Dec 3, 2025, 4:00 PM
NextCure Provides Update on ADC Programs and Financial Outlook
NXTC
New Projects/Investments
Guidance Update
M&A
- NextCure anticipates reporting Phase 1 dose escalation data for its antibody-drug conjugates (ADCs) SIM0505 and LNCB74 in the first half of 2026.
- The company in-licensed SIM0505 in June 2025, which has demonstrated strong safety and initial clinical responses in Phase 1 trials, leveraging a unique topoisomerase inhibitor payload.
- LNCB74 has shown extreme safety in trials, allowing for higher dose escalation, and utilizes a stable linker system with a tubulin inhibitor payload.
- With a little less than $50 million in cash (including a recent $21.5 million PIPE), NextCure projects its financial runway into the first half of 2027, covering key data readouts.
- NextCure plans an additional financing round in early 2026 to support the advancement of its programs into Phase 2.
Dec 3, 2025, 4:00 PM
NextCure Closes $21.5 Million PIPE Financing
NXTC
Equity Offering
- NextCure, Inc. closed a private placement (PIPE) financing on November 14, 2025, raising approximately $21.5 million in gross proceeds.
- The financing included the sale of 708,428 shares of common stock at $8.52 per share and pre-funded warrants to purchase up to 1,815,049 shares of common stock at $8.519 per pre-funded warrant.
- This capital infusion is projected to extend the company's cash runway into the first half of 2027, covering the planned first half of 2026 proof of concept data readouts for its SIM0505 and LNCB74 programs.
- The PIPE was led by Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, and Exome Asset Management.
Nov 17, 2025, 1:20 PM
NextCure announces private placement
NXTC
New Projects/Investments
- NextCure, Inc. has entered into definitive agreements for a private placement of 2,523,477 shares of common stock (or pre-funded warrants) at a purchase price of $8.52 per share.
- The private placement is expected to generate approximately $21.5 million in gross proceeds and is anticipated to close on or about November 13, 2025.
- The offering, priced at-the-market under Nasdaq rules, included participation from institutional and accredited investors such as Ikarian Capital, Squadron Capital Management, Affinity Healthcare Fund, LP., and Exome Asset Management.
- The net proceeds will be used for general working capital, extending the company's cash runway into the first half of 2027, and for proof of concept data readouts on its SIM0505 (CDH6 ADC) and LNCB74 (B7-H4 ADC) programs.
Nov 12, 2025, 1:00 PM
NextCure Reports Q3 2025 Financial Results and Provides Business Update
NXTC
Earnings
Guidance Update
New Projects/Investments
- NextCure, Inc. reported a net loss of $8.6 million for the third quarter ended September 30, 2025, with research and development expenses of $6.1 million and general and administrative expenses of $2.8 million.
- As of September 30, 2025, the company held $29.1 million in cash, cash equivalents, and marketable securities, which are projected to fund operations and capital expenditures into mid-2026.
- The company announced that the first U.S. patient was dosed in October 2025 for its SIM0505 (CDH6 ADC) program, and it received FDA acceptance for a protocol amendment for LNCB74 (B7-H4 ADC) to add higher dose escalation cohorts.
- Proof of concept data readouts for both SIM0505 and LNCB74 are anticipated in the first half of 2026.
Nov 5, 2025, 9:16 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more